CSL buys Talecris for $3.1bn in cash and debt; withdrawn
- Large Molecule
- Full Acquisition
- Payment Includes Cash
- Acquisition of Private Biotech
- Intra-Biotech Deal
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.